Facebook
Twitter
LinkedIn
Forward| Session |
Date |
|---|---|
| Pediatric acute leukemia with ETV6 alterations | 08/09/2023 - 12:00pm to 1:00pm CDT |
| Adolescent with SHH, TP53-mut Medulloblastoma: School aged male with WNT subtype (and co-occurring SHH pathway activated (passenger)) medulloblastoma | 09/13/2023 - 12:00pm to 1:00pm CDT |
| Adolescent with thyroid follicular carcinoma and germline DICER1 variant/Adolescent with papillary thyroid carcinoma harboring NCOA4::RET fusion | 10/11/2023 - 12:00pm to 1:00pm CDT |
| CBFA2T3-fusion AML | 11/08/2023 - 12:00pm to 1:00pm CST |
| Toddler female with infant-type hemispheric glioma/School age female with high-grade glioma IDH-/H3-wildtype | 12/13/2023 - 12:00pm to 1:00pm CST |
| CIC-Rearranged Sarcoma | 02/14/2024 - 12:00pm to 1:00pm CST |
| Mesenchymal Tumors with CREB::CREM Fusion | 04/10/2024 - 12:00pm to 1:00pm CDT |
| Targeted Therapies in Cancer Predisposition Syndromes: MEK Inhibitors in NF1, mTOR Inhibitors in TSC, HIF2a Inhibitor in VHL. | 05/08/2024 - 12:00pm to 1:00pm CDT |